Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y271
UPID:
CLTR1_HUMAN
Alternative names:
Cysteinyl leukotriene D4 receptor; G-protein coupled receptor HG55; HMTMF81
Alternative UPACC:
Q9Y271; B2R954; D3DTE4; Q5JS94; Q8IV19
Background:
Cysteinyl leukotriene receptor 1, also known as Cysteinyl leukotriene D4 receptor, G-protein coupled receptor HG55, and HMTMF81, plays a pivotal role in mediating bronchoconstriction in asthma. It operates through a G-protein that activates a phosphatidylinositol-calcium second messenger system, responding primarily to LTD4, which leads to smooth muscle contraction and proliferation, edema, eosinophil migration, and damage to the lung's mucus layer.
Therapeutic significance:
Understanding the role of Cysteinyl leukotriene receptor 1 could open doors to potential therapeutic strategies.